Abstract
Atypical chemokine receptor CXCR7 (ACKR3) functions as a scavenger receptor for chemokine CXCL12, a molecule that promotes multiple steps in tumor growth and metastasis in breast cancer and multiple other malignancies. Although normal vascular endothelium expresses low levels of CXCR7, marked upregulation of CXCR7 occurs in tumor vasculature in breast cancer and other tumors. To investigate effects of endothelial CXCR7 in breast cancer, we conditionally deleted this receptor from vascular endothelium of adult mice, generating CXCR7ΔEND/ΔEND animals. CXCR7ΔEND/ΔEND mice appeared phenotypically normal, although these animals exhibited a modest 35±3% increase in plasma CXCL12 as compared with control. Using two different syngeneic, orthotopic tumor implant models of breast cancer, we discovered that CXCR7ΔEND/ΔEND mice had significantly greater local recurrence of cancer following resection, elevated numbers of circulating tumor cells and more spontaneous metastases. CXCR7ΔEND/ΔEND mice also showed greater experimental metastases following intracardiac injection of cancer cells. These results establish that endothelial CXCR7 limits breast cancer metastasis at multiple steps in the metastatic cascade, advancing understanding of CXCL12 pathways in tumor environments and informing ongoing drug development targeting CXCR7 in cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Balkwill F . Cancer and the chemokine network. Nat Rev Cancer 2004; 4: 540–550.
Ali S, Lazennec G . Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev 2007; 26: 401–420.
Teicher B, Fricker S . CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16: 2927–2931.
Orimo A, Gupta P, Sgroi D, Arenzana-Seisdedos F, Delaunay T, Naeem R et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335–348.
Zhang X, Jin X, Malladi S, Zou Y, Wen Y, Brogi E et al. Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell 2013; 154: 1060–1073.
Muller A, Homey B, Soto H, Ge N, Catron D, Buchanon M et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50–56.
Singh S, Srivastava S, Bhardwaj A, Owen L, Singh A . CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer 2010; 103: 1671–1679.
Hoellenriegel J, Zboralski D, Maasch C, Rosin N, Wierda W, Keating M et al. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood 2014; 123: 1032–1039.
Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y, Fuse H . Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci 2008; 99: 539–542.
Xu T, Shen H, Liu L, Shu Y . The impact of chemokine receptor CXCR4 on breast cancer prognosis: a meta-analysis. Cancer Epidemiol 2013; 37: 725–731.
Wald O, Shapira O, Izhar U . CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics 2013; 3: 26–33.
Miao Z, Luker K, Summers B, Berahovich R, Bhojani M, Rehemtulla A et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci USA 2007; 104: 15735–15740.
Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta K et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008; 283: 4283–4294.
Yao X, Zhou L, Han S, Chen Y . High expression of CXCR4 and CXCR7 predicts poor survival in gallbladder cancer. J Int Med Res 2011; 39: 1253–1264.
D'Alterio C, Consales C, Polimeno M, Franco R, Cindolo L, Portella L et al. Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr Cancer Drug Targets 2010; 10: 772–781.
Tachezy M, Zander H, Gebauer F, von Loga K, Pantel K, Izbicki J et al. CXCR7 expression in esophageal cancer. J Transl Med 2013; 11: 238.
Liberman J, Sartelet H, Flahaut M, Muhlethaler-Mottet A, Coulon A, Nyalendo C et al. Involvement of the CXCR7/CXCR4/CXCL12 axis in the malignant progression of human neuroblastoma. PLoS One 2012; 7: e43665.
D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L et al. A prognostic model comprising pT stage, N status and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neo-adjuvant resistant rectal cancer patients. Int J Cancer 2013; 135: 379–390.
Sierro F, Biben C, Martinez-Munoz L, Mellado M, Ransohoff R, Li M et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci USA 2007; 104: 14759–14764.
Gerrits H, van Ingen Schenau D, Bakker N, van Disseldorp A, Strik A, Hermens L et al. Early postnatal lethality and cardiovascular defects in CXCR7-deficient mice. Genesis 2008; 46: 235–245.
Madden S, Cook B, Nacht M, Weber W, Callahan M, Jiang Y et al. Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 2004; 165: 601–608.
Maishi N, Ohga N, Hida Y, Akiyama K, Kitayama K, Osawa T et al. CXCR7: a novel tumor endothelial marker in renal cell carcinoma. Pathol Int 2012; 62: 309–317.
Gőthert J, Gustin S, Hall M, Green A, Gőttgens B, Izon D et al. In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis. Blood 2005; 105: 2724–2732.
Liao Y, Day K, Damon D, Duling B . Endothelial cell-specific knockout of connexin 43 causes hypotension and bradycardia in mice. Proc Natl Acad Sci USA 2001; 98: 9989–9994.
Suárez Y, Fernández-Hernando C, Yu J, Gerber S, Harrison K, Pober J et al. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci USA 2008; 105: 14082–14087.
Ding B-S, Cao Z, Lis R, Nolan D, Guo P, Simons M et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature 2013; 505: 97–102.
Boldajipour B, Mahabaleshwar S, Kardash E, Reichman-Fried M, Blaser H, Minina S et al. Control of chemokine-guided cell migration by ligand sequestration. Cell 2008; 132: 463–473.
Luker K, Steele J, Mihalko L, Luker G . Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene 2010; 29: 4599–4610.
Coleman R . Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s–6249s.
Ewens A, Mihich E, Ehrke M . Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma. Anticancer Res 2005; 25: 3905–3915.
Luker K, Lewin S, Mihalko L, Schmidt B, Winkler J, Coggins N et al. Scavenging of CXCL12 by CXCR7 regulates tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene 2012; 31: 4570–4578.
Guillemot E, Karimdjee-Soilhi B, Pradelli E, Benchetrit M, Goquet-Surmenian E, Millet M et al. CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver. Br J Cancer 2012; 107: 1944–1949.
Dang S, Peng Y, Ye L, Wang Y, Qian Z, Chen Y et al. Stimulation of TLR4 by LMW-HA induces metastasis in human papillary thyroid carcinoma through CXCR7. Clin Dev Immunol 2013; 2013: 712561.
Xue T, Chen R, Han D, Chen J, Xue Q, Gao D et al. Down-regulation of CXCR7 inhibits the growth and lung metastasis of human hepatocellular carcinoma cells with highly metastatic potential. Exp Ther Med 2012; 3: 117–123.
Burns J, Summers B, Wang Y, Melikian A, Berahovich R, Miao Z et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006; 203: 2201–2213.
Goquet-Surmenian E, Richard-Fiardo P, Guillemot E, Benchetrit M, Gomez-Brouchet A, Buzzo P et al. CXCR7-mediated progression of osteosarcoma in the lungs. Br J Cancer 2013; 109: 1579–1585.
Walters M, Ebsworth K, Berahovich R, Penfold M, Liu S, Al Omran R et al. Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats. Br J Cancer 2014; 110: 1179–1188.
Berahovich R, Zabel B, Lewen S, Walters M, Ebsworth K, Wang Y et al. Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels. Immunology 2014; 141: 111–122.
Wang Y, Li G, Stanco A, Long J, Crawford D, Potter G et al. CXCR4 and CXCR7 have distinct functions in regulating interneuron migration. Neuron 2011; 69: 61–76.
Sanchez-Alcaniz J, Haege S, Mueller W, Pla R, Mackay F, Schulz S et al. Cxcr7 controls neuronal migration by regulating chemokine responsiveness. Neuron 2011; 69: 77–90.
Dona E, Barry J, Valentin G, Quirin C, Khmelinskii A, Kunze A et al. Directional tissue migration through a self-generated chemokine gradient. Nature 2013; 503: 285–289.
Venkiteswaran G, Lewellis S, Wang J, Reynolds E, Nicholson C, Knaut H . Generation and dynamics of an endogenous, self-generated signaling gradient across a migrating tissue. Cell 2013; 155: 674–687.
Cavnar S, Ray P, Moudgil P, Chang S, Luker K, Linderman J et al. Microfluidic source-sink model reveals effects of biophysically distinct CXCL12-isoforms in breast cancer chemotaxis. Integr Biol 2014; 6: 564–576.
Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004; 6: 17–32.
Potter S, Dwyer R, Curran C, Hennesy E, Harrington K, Griffin D et al. Systemic chemokine levels in breast cancer patients and their relationship with circulating menstrual hormones. Breast Cancer Res Treat 2009; 115: 279–287.
Zabel B, Wang Y, Lewen S, Berahovich R, Penfold M, Zhang P et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol 2009; 183: 3204–3211.
Kochetkova M, Kumar S, McColl S . Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death Differ 2009; 16: 664–673.
Sun Y, Mao X, Fan C, Liu C, Guo A, Guan S et al. CXCL12-CXCR4 axis promotes the natural selection of breast cancer cell metastasis. Tumour Biol 2014; 35: 7765–7773.
Cruz-Orengo L, Holman D, Dorsey D, Zhou L, Zhang P, Wright M et al. CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity. J Exp Med 2011; 208: 327–339.
Kitamura T, Qian B-Z, Pollard J . Immune cell promotion of metastasis. Nat Rev Immunol 2015; 15: 73–86.
Raggo C, Ruhl R, McAllister S, Koon H, Dezube B, Fruh K et al. Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus. Cancer Res 2005; 65: 5084–5095.
Totonchy J, Osborn J, Botto S, Clepper L, Moses A . Aberrant proliferation in CXCR7+ endothelial cells via degradation of the retinoblastoma protein. PLoS One 2013; 8: e69828.
Casanovas O, Hicklin D, Bergers G, Hanahan D . Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299–309.
Nanda A, Karim B, Peng Z, Liu G, Qiu W, Gan C et al. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc Natl Acad Sci USA 2006; 103: 3351–3356.
Cullen M, Seaman S, Chaudhary A, Yang M, Hilton M, Logsdon D et al. Host-derived tumor endothelial marker 8 promotes the growth of melanoma. Cancer Res 2009; 69: 6021–6026.
Yokoyama K, Ishikawa N, Igarahsi S, Kawano N, Hattori K, Miyazaki T et al. Discovery of potent CCR4 antagonists: synthesis and structure-activity relationship study of 2,4-diaminoquinazolines. Bioorg Med Chem 2008; 16: 7021–7031.
Walters M, Ebsworth K, Sullivan T, Zhang P, Powers J, Jaen J et al. CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens. Immunol Lett 2013; 151: 44–47.
Smith M, Luker K, Garbow J, Prior J, Jackson E, Piwnica-Worms D et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004; 64: 8604–8612.
Ray P, Mihalko L, Coggins N, Moudgil P, Ehrlich A, Luker K et al. Carboxy-terminus of CXCR7 regulates receptor localization and function. Int J Biochem Cell Biol 2012; 44: 669–678.
Luker G, Pica C, Song J, Luker K, Piwnica-Worms D . Imaging 26 S proteasome activity and inhibition in living mice. Nat Med 2003; 9: 969–973.
Fenner J, Stacer A, Winterroth F, Johnson T, Luker K, Luker G . Macroscopic stiffness of breast tumors predicts metastasis. Sci Rep 2014; 4: 5512.
Salomonnson E, Stacer A, Ehrlich A, Luker K, Luker G . Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy. PLoS One 2013; 8: e51500.
Zhao S, Chang S, Linderman J, Feng F, Luker G . A comprehensive analysis of CXCL12 isoforms in breast cancer. Transl Oncol 2014; 7: 429–438.
Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545–15550.
Acknowledgements
We thank Dr Mark Penfold and ChemoCentryx for CXCR7 loxP mice and antibody 11G8. Dr Jun-Lin Guan provided SCL CreERT through courteous permission of Dr Glenn Begley. We thank Dr Aaron Robida from the University of Michigan Flow Cytometry Core for assistance. Research was supported by United States National Institute of Health grants R21CA182333, R01CA136553, R01CA142750, R01CA170198 and P50CA093990.
Author Contributions
ACS, JF, SPC, KS and GDL performed experiments and analyzed data. KEL contributed new reagents. SZ and SLC performed GSEA analyses. KEL and GDL conceptualized and directed the research. ACS, JF, SPC and GDL wrote the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Stacer, A., Fenner, J., Cavnar, S. et al. Endothelial CXCR7 regulates breast cancer metastasis. Oncogene 35, 1716–1724 (2016). https://doi.org/10.1038/onc.2015.236
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2015.236
This article is cited by
-
How chemokines organize the tumour microenvironment
Nature Reviews Cancer (2024)
-
Roles of NOLC1 in cancers and viral infection
Journal of Cancer Research and Clinical Oncology (2023)
-
Atypical chemokine receptor 3 induces colorectal tumorigenesis in mice by promoting β-arrestin-NOLC1-fibrillarin-dependent rRNA biogenesis
Acta Pharmacologica Sinica (2022)
-
Downregulation of CXCL12 in mesenchymal stromal cells by TGFβ promotes breast cancer metastasis
Oncogene (2017)